Abstract Library

#4574 Long-acting somatostatin analogue injections for treating gastroenteropancreatic neuroendocrine tumours (GEP-NETs) and acromegaly: BackSOM – A patient preference study

Introduction: Long-acting somatostatin analogues, lanreotide and octreotide, are indicated for first-line treatment of GEP-NETs and acromegaly. Lanreotide was approved in 2007 in Europe, and is supplied as a prefilled, ready-to-use syringe (LAN-PF). In 2021, a generic form of lanreotide was released and supplied in a syringe requiring assembly (LAN-RA). To ensure patient compliance with treatment, it is important to understand their injection experiences.

Conference:

Presenting Author: Hernando Cubero J

Authors: Rodien-Louw C, Simo-Servat A, Dubois M, Sheppard J, McDonnell M,

Keywords: gastroenteropancreatic neuroendocrine tumour, GEP-NET, acromegaly, lanreotide, LA-SSA, somatostatin, patient preference,

#4399 Updated data from a single-arm, open-label, multicentre clinical study on the efficacy and safety of surufatinib combined with EP regimen and serplulimab in first-line treatment of NEC

Introduction: NEC is an aggressive neuroendocrine neoplasm with limited treatment options. Surufatinib (SUR), a kinase inhibitor targeting VEGFRs, FGFR-1, and CSF-1R, improves vascular normalisation and tumour microenvironment, synergising with chemo- and immunotherapy.

Conference:

Presenting Author: Lin Z

Authors: Zhang T, Lin Z, Zhao L, Ma H, Zhang D,

Keywords: NEC, surufatinib, EP, first-line,

#4374 Efficacy and safety of immunotherapy combined with antiangiogenesis agents and temozolomide in neuroendocrine carcinoma

Introduction: Platinum-based doublet chemotherapy is the standard first-line treatment, without standard treatment for second-line or subsequent systemic therapy for recurrent or progressive advanced neuroendocrine cancer (NEC).

Conference:

Presenting Author:

Authors: Li X, Yang M, Fan Q, Song L,

Keywords: Neuroendocrine carcinoma, Immunotherapy, Antiangiogenesis agents, Temozolomide,

#4190 Burden of medication in patients with lung neuroendocrine tumors (NETs) in a US real-world setting

Introduction: Real-world evidence on patients with lung NETs, specifically on comorbidities and the prevalence of carcinoid syndrome (CS), is lacking.

Conference:

Presenting Author:

Authors: Starr J, Houchard A, Pommie C, Ribeiro-Oliveira Jr A, Chan J,

Keywords: lung, neuroendocrine tumor, concomitant medication, costs,

#4135 ALK-targeted therapy in atypical carcinoid of the lung: A case report

Introduction: Atypical pulmonary carcinoids with anaplastic lymphoma kinase (ALK) rearrangement are extremely rare. The effectiveness of ALK-targeted therapy in such individuals remains unclear. This article reports a patient diagnosed with ALK-positive metastatic atypical carcinoid (AC) of the lung, who achieved tumor remission following first-line treatment with alectinib.

Conference:

Presenting Author:

Authors: Sun Y, Tan H, Ying J, Jiang L, Chi Y,

Keywords: neuroendocrine tumor of the lung, anaplastic lymphoma kinase, alectinib, atypical carcinoid,